Holen Sie sich die Stockscreener-App
3.31
12.01%
0.355
Handel nachbörslich:
3.24
-0.07
-2.11%
Vistagen Therapeutics Inc Aktie (VTGN) Neueste Nachrichten
Vistagen Therapeutics’ Earnings Call: Progress Amid Challenges - MSN
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2026 Earnings Call Transcript - MSN
Vistagen Therapeutics Inc. Q1 Earnings Call Highlights: Progress Amid Challenges and Financial Pressures. - AInvest
Vistagen (VTGN) Q1 R&D Expense Jumps 54% - AOL.com
VistaGen Therapeutics (NASDAQ:VTGN) Issues Quarterly Earnings Results - MarketBeat
Is Vistagen Therapeutics Inc. stock a good dividend stockGame-Changing Investment Alerts - thegnnews.com
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates - MSN
Vistagen signals Q4 2025 Phase III data readout for fasedienol as pipeline advances - MSN
Vistagen Therapeutics (VTGN) Advances Phase III Trials for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid Financial Challenges - GuruFocus
Earnings call transcript: VistaGen Therapeutics’ Q1 2025 sees increased R&D costs - Investing.com Nigeria
Earnings call transcript: VistaGen Therapeutics’ Q1 2025 sees increased R&D costs By Investing.com - Investing.com South Africa
Vistagen 2026 Q1 Earnings Widened Losses Despite Surging Revenue - AInvest
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - BioSpace
Aon Appoints Jo Ann Jenkins to Board of Directors - AInvest
Vistagen Reports Q1 Earnings, Advances Key Programs Across Pipeline - AInvest
Vistagen Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
VistaGen Therapeutics (VTGN): Clinical Catalysts and Financial Pressures—Is the Biopharma Still Worth the Gamble? - AInvest
VistaGen Therapeutics Inc Q1 Sales Increase - Nasdaq
VistaGen Reports Q1 2026 Financial Results and Update - TipRanks
Vistagen reports Q1 EPS (47c), consensus (44c) - TipRanks
VistaGen Therapeutics: Balancing Burn with Biotech Breakthroughs in a High-Stakes Race - AInvest
Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView
Biopharmaceutical firm VistaGen Q1 net loss widens - MarketScreener
Market reaction to Vistagen Therapeutics Inc.’s recent newsValue Investing Checklist with Entry Signals - Newser
Insights Ahead: VistaGen Therapeutics's Quarterly Earnings - 富途牛牛
What makes Vistagen Therapeutics Inc. stock price move sharplyTechnical Chart Summary for Momentum Stocks - Newser
How to track smart money flows in Vistagen Therapeutics Inc.Stock Portfolio Risk and Return Analysis - Newser
Will Vistagen Therapeutics Inc. see short term momentumBuy Zone Strategy with Pattern Recognition - Newser
Is Vistagen Therapeutics Inc. stock a good hedge against inflationDaily Stock Movement Forecast with Accuracy - Newser
Using R and stats models for Vistagen Therapeutics Inc. forecastingMachine Learning Stock Movement Detector - Newser
Using Python tools to backtest Vistagen Therapeutics Inc. strategiesShort Term Gain Strategy with AI Logic - Newser
VistaGen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Vistagen VTGN 2026Q1 Earnings Preview Upside Potential on Neuroscience Pipeline Progress - AInvest
Evaluating Vistagen Therapeutics Inc. with trendline analysisFree Real-Time Analysis With Entry Targets - Newser
Real Time Chart Alerts Flash Bullish on Vistagen Therapeutics Inc.Entry Alert With Low Drawdown Strategy Noted - beatles.ru
Intraday pattern recognizer results for Vistagen Therapeutics Inc.Daily Upside Movement Prediction With Data - Newser
What are analysts’ price targets for Vistagen Therapeutics Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
Is it the right time to buy Vistagen Therapeutics Inc. stockRapidly expanding wealth - Jammu Links News
Does Vistagen Therapeutics Inc. stock perform well during market downturnsFree Consultation - Jammu Links News
Should I hold or sell Vistagen Therapeutics Inc. stock in 2025Free Stock Market Trend Analysis - Jammu Links News
Is Vistagen Therapeutics Inc. a growth stock or a value stockConsistently profitable trades - Jammu Links News
What analysts say about Vistagen Therapeutics Inc. stockGet daily updates on promising stocks - Jammu Links News
How many analysts rate Vistagen Therapeutics Inc. as a “Buy”Outstanding capital returns - Jammu Links News
How volatile is Vistagen Therapeutics Inc. stock compared to the marketDiscover market opportunities with expert help - Jammu Links News
When is Vistagen Therapeutics Inc. stock expected to show significant growthMaximize your gains with expert trading tips - Jammu Links News
What institutional investors are buying Vistagen Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
What are the technical indicators suggesting about Vistagen Therapeutics Inc.Build wealth with high-performing stocks - Jammu Links News
Published on: 2025-08-03 02:29:23 - Jammu Links News
Vistagen Therapeutics Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - Jammu Links News
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):